ERCC2 and urinary bladder cancer: While this approach clearly demonstrated a cisplatin sensitizing effect of clinically observed ERCC2 HD mutations (Figure 2), it does not fully recapitulate the genetic context of bladder cancer because most ERCC2-mutant bladder tumors harbor a heterozygous missense ERCC2 mutation without accompanying LOH (Supplemental Figure 1G).